Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 3/20 | 0.49 |
| ▸ | CNR2 | P34972 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.48 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.48 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.48 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.47 |
| ▸ | FGF1 | P05230 | 1/20 | 0.47 |
| ▸ | FGF2 | P09038 | 1/20 | 0.47 |
| ▸ | VEGFA | P15692 | 1/20 | 0.47 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.47 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179912 | 1.00 | TDP1 (0.55) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL14417100 | 1.00 | TDP1 (0.55) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL12569327 | 1.00 | TDP1 (0.55) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL18780618 | 1.00 | TDP1 (0.55) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL6033324 | 1.00 | TDP1 (0.55) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL3622089 | 0.99 | TDP1 (0.54) | TDP1CA12CA1CA2CA9 | |
| Biotin SCHEMBL1039790 | 0.97 | TDP1 (0.54) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL20537344 | 0.93 | TDP1 (0.55) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL1693977 | 0.93 | TDP1 (0.53) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL565520 | 0.93 | TDP1 (0.53) | TDP1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552202-B1 | METHODS AND COMPOSITIONS FOR WEIGHT LOSS | SDG INC (US) | 2023-07-26 | — | — | EP | claimed |
| EP-2552202-B1 | METHODS AND COMPOSITIONS FOR WEIGHT LOSS | SDG INC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-9145453-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9034372-B2 | Lipid construct for delivery of insulin to a mammal | SDG, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20150125518-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. | 2015-05-07 | — | — | US | disclosed |
| US-8962015-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20150031608-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG, INC. | 2015-01-29 | — | — | US | disclosed |
| US-8846053-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140243430-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20130267462-A1 | Lipid Construct for Delivery of Insulin to a Mammal | SDG, INC. | 2013-10-10 | — | — | US | disclosed |
| US-20130183270-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20090087479-A1 | Orally bioavailable lipid-based constructs | SDG, INC. ( AN OHIO CORPORATION) (US) | 2009-04-02 | — | — | US | disclosed |
| US-20070218117-A1 | Supra molecular construct for delivery of interferon to a mammal | SDG, INC. | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070218117-A1 | Supra molecular construct for delivery of interferon to a mammal | HAVCR2, IFNAR1, MSR1 | TDP1 4728/4885CA12 3516/4885CA1 4190/4885 |
| US-20150125518-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, FABP6 | TDP1 4819/4885CA12 3452/4885CA1 2966/4885 |
| US-20130183270-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, FABP1, LIPC | TDP1 4742/4885CA12 3441/4885CA1 2920/4885 |
| US-20090087479-A1 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | TDP1 4757/4885CA12 2422/4885CA1 2202/4885 |
| US-20140243430-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, LIPC, FABP6 | TDP1 4650/4885CA12 1226/4885CA1 2890/4885 |
| US-20150031608-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | INSR, IAPP, GPR119 | TDP1 4882/4885CA12 2944/4885CA1 2697/4885 |
| US-20130267462-A1 | Lipid Construct for Delivery of Insulin to a Mammal | INSR, IAPP, GPR119 | TDP1 4882/4885CA12 2944/4885CA1 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.